FMP
Agile Therapeutics, Inc.
AGRX
NASDAQ
Inactive Equity
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
1.51 USD
0.05 (3.31%)
AGRX Financial Statements
Quarter
2024 Q2
2024 Q1
2023 Q4
2023 Q3
Total Revenue
5.58M
5.72M
3.61M
6.66M
Cost of Revenue
1.5M
1.68M
2.19M
2.48M
Gross Profit
4.08M
4.04M
1.42M
4.18M
Operating Expenses
6.83M
6.79M
5.47M
8.19M
Research and Development
538k
495k
54k
705k
Selling, General & Administrative Expenses
6.29M
6.3M
5.42M
7.48M
Selling & Marketing Expenses
3.78M
3.68M
3.73M
4.8M
General & Administrative Expenses
2.51M
2.62M
1.69M
2.68M
Other Expenses
0
0
0
0
Operating Income
-2.75M
-2.76M
-4.05M
-4M
Total Other Income/Expenses Net
-9.13M
4.04M
-418k
3.2M
Income Before Tax
-11.87M
1.28M
-4.47M
-799k
Income Tax
0
185k
305k
-98k
Net Income
-11.87M
1.28M
-4.47M
-799k
Basic EPS
-1.73
0.28
-1.51
-0.27
EPS Diluted
-1.73
0.28
-1.51
-0.27
Basic Average Shares
6.86M
4.63M
2.96M
2.95M
Diluted Average Shares
6.86M
4.63M
2.96M
2.95M
EBITDA
-2.75M
-2.63M
-3.94M
-360k
All figures are in USD.
